December 07, 2020
An off-the-shelf CAR T-cell therapy that targets B-cell maturation antigen, ALLO-715, elicited responses in heavily pretreated patients with relapsed/refractory multiple myeloma in early findings from a first-in-human study presented at the 2020 ASH Meeting.
December 07, 2019
Mosunetuzumab generated durable responses in patients with highly refractory non-Hodgkin lymphomas.